Journal of the Endocrine Society · 2026
Intermediate risk thyroid cancer management: physician survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suresh Annu R, Kung Amanda, Chou Jiling, Jonklaas Jacqueline
Аннотация
CONTEXT: Variability exists in the use of radioactive iodine (RAI) treatment in intermediate-risk (IR) thyroid cancer.
OBJECTIVE: The study surveyed clinicians about their use of RAI in theoretical cases of patients with IR thyroid cancer.
DESIGN: A survey presented patient cases with pathology results and 2 variations consisting of baseline thyroglobulin levels of ≤5 and >5 ng/mL. Respondents were queried as to their use of RAI therapy in each case. Univariate Bayesian cumulative ordinal regression models were used to evaluate the relationships between selected predictors and the response.
SETTING: Online survey.
PARTICIPANTS: American Thyroid Association members.
INTERVENTION: Participants responded regarding their management of 15 patient cases of IR thyroid cancer.
MAIN OUTCOME MEASURES: Use of RAI therapy, consisting of no RAI or doses of ∼30, 40 to 74, 75 to 100, or >100 mCi.
RESULTS: Members were surveyed in May and June, 2024. Using matched vignettes, respondents were more likely to recommend RAI doses of ≥30 mCi and more likely to recommend higher RAI doses in general when thyroglobulin levels were >5 ng/mL compared with ≤5 ng/mL (odds ratios [ORs] 2.89-18.28). Examining unadjusted associations within the case scenarios presented, the presence of lymph nodes measuring 0.2-3 cm, more than 5 positive lymph nodes, and lateral lymph nodes were associated with higher RAI dose recommendations (unadjusted ORs 2.33-26.16).
CONCLUSION: Within the IR category, there were specific pathology and biochemical findings associated with greater likelihood of the clinician recommending RAI therapy. These findings may be instructive in understanding how these features are perceived to add to the risk of thyroid cancer recurrence.
OBJECTIVE: The study surveyed clinicians about their use of RAI in theoretical cases of patients with IR thyroid cancer.
DESIGN: A survey presented patient cases with pathology results and 2 variations consisting of baseline thyroglobulin levels of ≤5 and >5 ng/mL. Respondents were queried as to their use of RAI therapy in each case. Univariate Bayesian cumulative ordinal regression models were used to evaluate the relationships between selected predictors and the response.
SETTING: Online survey.
PARTICIPANTS: American Thyroid Association members.
INTERVENTION: Participants responded regarding their management of 15 patient cases of IR thyroid cancer.
MAIN OUTCOME MEASURES: Use of RAI therapy, consisting of no RAI or doses of ∼30, 40 to 74, 75 to 100, or >100 mCi.
RESULTS: Members were surveyed in May and June, 2024. Using matched vignettes, respondents were more likely to recommend RAI doses of ≥30 mCi and more likely to recommend higher RAI doses in general when thyroglobulin levels were >5 ng/mL compared with ≤5 ng/mL (odds ratios [ORs] 2.89-18.28). Examining unadjusted associations within the case scenarios presented, the presence of lymph nodes measuring 0.2-3 cm, more than 5 positive lymph nodes, and lateral lymph nodes were associated with higher RAI dose recommendations (unadjusted ORs 2.33-26.16).
CONCLUSION: Within the IR category, there were specific pathology and biochemical findings associated with greater likelihood of the clinician recommending RAI therapy. These findings may be instructive in understanding how these features are perceived to add to the risk of thyroid cancer recurrence.